BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BC Extra | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

Cancer and generics company CASI Pharmaceuticals Inc. (NASDAQ:CASI) promoted Larry Zhang to president. He was president of the cancer and generics company's Chinese subsidiary CASI Pharmaceuticals (Beijing) Co. Ltd. Prior to joining CASI, Zhang was...
BC Innovations | Jun 25, 2019
Distillery Therapeutics

Herb-derived flavonoid identified as potential TNBC treatment

DISEASE CATEGORY: Cancer INDICATION: Breast cancer The natural product wogonoside, a SMO inhibitor, could help treat triple-negative breast cancer (TNBC), a new indication for SMO inhibition. Wogonoside is a flavonoid found in the herb Scutellaria...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden...
BC Extra | Sep 25, 2018
Company News

Management tracks: Curis, Gemphire

Cancer company Curis Inc. (NASDAQ:CRIS) named COO James Dentzer president and CEO and appointed him as a board member. He replaces Ali Fattaey, who is departing. Curis had promoted Dentzer to COO this year. Cardiometabolic...
BC Innovations | Jul 19, 2018
Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
BC Week In Review | Jun 1, 2018
Clinical News

Fast Track designation for Curis' lymphoma therapy

Curis Inc. (NASDAQ:CRIS) said FDA granted Fast Track designation to fimepinostat (formerly CUDC-907) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in a third-line setting. The product is an oral dual phosphoinositide...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Innovations | Sep 19, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer In vitro and mouse studies identified a hedgehog pathway inhibitor that could help treat medulloblastoma. Optimization and testing in mouse fibroblast cell-based assays of a previously identified dihydrobenzooxazocin analog yielded a compound...
Items per page:
1 - 10 of 379
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
BC Extra | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

Cancer and generics company CASI Pharmaceuticals Inc. (NASDAQ:CASI) promoted Larry Zhang to president. He was president of the cancer and generics company's Chinese subsidiary CASI Pharmaceuticals (Beijing) Co. Ltd. Prior to joining CASI, Zhang was...
BC Innovations | Jun 25, 2019
Distillery Therapeutics

Herb-derived flavonoid identified as potential TNBC treatment

DISEASE CATEGORY: Cancer INDICATION: Breast cancer The natural product wogonoside, a SMO inhibitor, could help treat triple-negative breast cancer (TNBC), a new indication for SMO inhibition. Wogonoside is a flavonoid found in the herb Scutellaria...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden...
BC Extra | Sep 25, 2018
Company News

Management tracks: Curis, Gemphire

Cancer company Curis Inc. (NASDAQ:CRIS) named COO James Dentzer president and CEO and appointed him as a board member. He replaces Ali Fattaey, who is departing. Curis had promoted Dentzer to COO this year. Cardiometabolic...
BC Innovations | Jul 19, 2018
Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
BC Week In Review | Jun 1, 2018
Clinical News

Fast Track designation for Curis' lymphoma therapy

Curis Inc. (NASDAQ:CRIS) said FDA granted Fast Track designation to fimepinostat (formerly CUDC-907) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in a third-line setting. The product is an oral dual phosphoinositide...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Innovations | Sep 19, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer In vitro and mouse studies identified a hedgehog pathway inhibitor that could help treat medulloblastoma. Optimization and testing in mouse fibroblast cell-based assays of a previously identified dihydrobenzooxazocin analog yielded a compound...
Items per page:
1 - 10 of 379